MURABUTIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H40N4O11
Molecular Weight	548.5839
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O

InChI

InChIKey=ISYJGPYKJNWIQE-BNOMVYTKSA-N

InChI=1S/C23H40N4O11/c1-5-6-9-37-23(36)15(7-8-18(24)32)27-21(34)12(2)25-22(35)13(3)38-20(19(33)17(31)11-29)16(10-28)26-14(4)30/h10,12-13,15-17,19-20,29,31,33H,5-9,11H2,1-4H3,(H2,24,32)(H,25,35)(H,26,30)(H,27,34)/t12-,13+,15+,16-,17+,19+,20+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C23H40N4O11
Molecular Weight	548.5839
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/31054162 | https://www.ncbi.nlm.nih.gov/pubmed/29688119 | https://www.ncbi.nlm.nih.gov/pubmed/24554695 | https://www.ncbi.nlm.nih.gov/pubmed/22855691

Murabutide is a safe synthetic immunomodulator derived from muramyl dipeptide, the smallest bioactive unit of bacterial peptidoglycan. In contrast to muramyl dipeptide, Murabutide is devoid of pyrogenic activity and lacks somnogenic activity. Murabutide acts as a ligand for the intracellular receptor NOD2 and has the capacity to synergize with selected therapeutic cytokines to drive the release of Th1 cytokines. Murabutide has been found to suppress human immunodeficiency virus type-1 (HIV-1) replication, in macrophages, through regulated expression of cellular factors needed at different steps in the virus replication cycle.

Originator

Approval Year

PubMed

Title	Date	PubMed
NOD2 agonist murabutide alleviates radiation-induced injury through DNA damage response pathway mediated by ATR.	2019-11	31054162
Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.	2001-08	11435574

Patents

Sample Use Guides

In Vivo Use Guide

7 mg on 5 consecutive days per week, for a period of 6 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:03:27 GMT 2025` Edited by `admin` on `Mon Mar 31 18:03:27 GMT 2025`
Record UNII	88121G1PKA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

2-ACETAMIDO-3-O-((R)-1-(((S)-1-(((R)-3-CARBAMOYL-1-CARBOXYPROPYL)CARBAMOYL)ETHYL)CARBAMOYL)ETHYL)-2-DEOXY-D-GLUCOPYRANOSE, BUTYL ESTER

Preferred Name

English

MURABUTIDE

Official Name

English

murabutide [INN]

Common Name

English

Code System Code Type Description

EVMPD

SUB09095MIG